Metrics to compare | PROGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPROGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | 9.0x | −0.4x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 1.0x | 2.3x | 2.6x | |
Price / LTM Sales | 46.8x | 3.3x | 3.0x | |
Upside (Analyst Target) | - | 12.6% | 55.7% | |
Fair Value Upside | Unlock | 15.0% | 8.1% | Unlock |
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka Strand, Sweden.